Oruka Therapeutics, Inc. Proceeds from Income Tax Refunds
Oruka Therapeutics, Inc. (ORKA) reported Proceeds from Income Tax Refunds of $9.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIncomeTaxRefunds · last filed 2022-03-14
- Oruka Therapeutics, Inc. proceeds from income tax refunds for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- Oruka Therapeutics, Inc. proceeds from income tax refunds for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- Oruka Therapeutics, Inc. proceeds from income tax refunds for the quarter ending 2019-12-31 was $16.00K, a 30.43% decline year-over-year.
- Oruka Therapeutics, Inc. proceeds from income tax refunds for the quarter ending 2019-09-30 was $42.00K.
- Oruka Therapeutics, Inc. proceeds from income tax refunds for fiscal 2020 was $9.00K, a 94.61% decline from fiscal 2019.
- Oruka Therapeutics, Inc. proceeds from income tax refunds for fiscal 2019 was $167.00K, a 209.26% increase from fiscal 2018.
- Oruka Therapeutics, Inc. proceeds from income tax refunds for fiscal 2018 was $54.00K, a 42.11% increase from fiscal 2017.
- Oruka Therapeutics, Inc. proceeds from income tax refunds for fiscal 2017 was $38.00K.
| Period end | Proceeds from Income Tax Refunds 3 month | Proceeds from Income Tax Refunds 6 month | Proceeds from Income Tax Refunds 9 month | Proceeds from Income Tax Refunds 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $0.00 derived: sum of 2 quarters · filed 2022-03-14 | $9.00K 10-K · filed 2022-03-14 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $9.00K 10-Q · filed 2021-11-02 | ||
| 2020-06-30 | $9.00K 10-Q · filed 2021-08-04 | |||
| 2019-12-31 | $16.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $58.00K derived: sum of 2 quarters · filed 2021-03-18 | $85.00K derived: sum of 3 quarters · filed 2021-03-18 | $167.00K 10-K · filed 2021-03-18 |
| 2019-09-30 | $42.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-02 | $69.00K derived: sum of 2 quarters · filed 2020-11-02 | $151.00K 10-Q · filed 2020-11-02 | $174.00K derived: sum of 4 quarters · filed 2020-11-02 |
| 2019-06-30 | $27.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $109.00K 10-Q · filed 2020-08-05 | $132.00K derived: sum of 3 quarters · filed 2020-08-05 | |
| 2019-03-31 | $82.00K 10-Q · filed 2020-05-06 | $105.00K derived: sum of 2 quarters · filed 2020-05-06 | ||
| 2018-12-31 | $23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-18 | $54.00K 10-K · filed 2020-02-18 | ||
| 2018-09-30 | $31.00K 10-Q · filed 2019-11-06 | |||
| 2017-12-31 | $38.00K 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |